About: http://data.cimple.eu/news-article/8f902198de4c31177c7639d55ac193c53b00336ce196946b5056036f     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • German pharmaceutical giant Bayer said Monday it will buy US-based biotech firm Asklepios BioPharmaceutical for as much as $4 billion as it aims to get a foothold in the rapidly growing gene-therapy market. "With this acquisition, Bayer significantly advances the establishment of a cell and gene therapy platform that can be at the forefront of breakthrough science," chief executive Werner Baumann said in a statement. Bayer, which hopes to close the deal by the end of the year, said it will pay $2 billion (1.7 billion euros) upfront and a further $2 billion in milestone payments, 75 percent of which will be paid over the next five years. North Carolina-based AskBio, founded in 2001, specialises in the research, development and manufacturing of gene therapies and has in its pipeline treatments for Parkinson's disease and congestive heart failure. Bayer's previous investments in biotechnology include the acquisition of cell-therapy focused BlueRock Therapeutics for up to $1 billion in 2019. The sprawling German company lost 9.5 billion euros in the second quarter of this year, reflecting legal costs after its controversial purchase of Monsanto for $63 billion in 2018. It expects to save 1.5 billion euros by 2024, on top of the 2.6 billion euros of annual savings it expects to make from 2022, Bayer said earlier in October. edf/dlc/bmm
schema:headline
  • Bayer spends up to $4 bn on US biotech firm AskBio
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software